8-KRegulation FD

Elevance Health, Inc. 8-K Report, Regulation FD Disclosure (Jun 9, 2020)

Filed June 9, 2020For Securities:ELV

Summary

Elevance Health, Inc. (formerly Anthem, Inc.), in its 8-K filing dated June 9, 2020, provided an update on its financial outlook for the full year 2020. The company reaffirmed its net income guidance to be greater than $21.00 per share, anticipating approximately $1.30 per share in net unfavorable items. Consequently, the adjusted net income guidance remains strong, expected to exceed $22.30 per share. Significantly, Elevance Health also adjusted its earnings distribution expectations, now forecasting that approximately 70% of its adjusted earnings per share will be generated in the first half of 2020. This update does not incorporate any new adjustment items beyond what was previously disclosed in the first quarter earnings release. Investors should note that this information was provided as Regulation FD disclosure and is subject to the company's standard forward-looking statements disclaimer, highlighting various risks and uncertainties that could impact actual results.

Key Highlights

  • 1Reaffirmed full-year 2020 net income guidance exceeding $21.00 per share.
  • 2Anticipates approximately $1.30 per share in net unfavorable items for the full year.
  • 3Maintained adjusted net income guidance to be greater than $22.30 per share.
  • 4Expects approximately 70% of adjusted earnings per share to be generated in the first half of 2020.
  • 5Guidance does not include any adjustment items beyond those reported in the Q1 2020 earnings release.
  • 6Information provided under Regulation FD Disclosure.
  • 7Includes standard forward-looking statements disclaimer with numerous risk factors outlined.

Frequently Asked Questions

Elevance Health reaffirmed its net income guidance to be greater than $21.00 per share for the full year 2020. After accounting for approximately $1.30 per share in net unfavorable items, the company continues to expect adjusted net income to be greater than $22.30 per share.

The company now expects to generate approximately 70 percent of its adjusted earnings per share in the first half of the year, indicating a stronger performance anticipated in the initial six months of 2020.

No, this guidance does not include any new adjustment items beyond those that were already reported in Elevance Health's first quarter 2020 earnings release. The company is reaffirming its previous outlook with this updated distribution expectation.

This 8-K filing serves as a Regulation FD disclosure, providing investors with important updates on the company's financial outlook and earnings expectations. It's crucial for investors to note the forward-looking nature of this information and the associated risks mentioned in the filing.